ENL 46.54 Reed Elsevier Nv $ENL Hit a 52 week high of 46.54

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2014 at 10:47 AM

ENL 46.54 Reed Elsevier Nv $ENL Hit a 52 week high of 46.54 Closing the day 09:43 at 46.54 -0.23 -0.49% With a day low of 46.48 and a total volume of 5,990.

ENL Recent Posts: http://investorshangout.com/Reed-Elsevier-NV-ENL-50879/

ENL Reed Elsevier Nv Recent Headline News

Elsevier Expands Neuroscience Portfolio With Eight New Books
Marketwire Canada - 2 hrs 2 mins ago
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the expansion of its neuroscience portfolio with eight new neuroscience books. These include the long-awaited fourth edition of The Rat Nervous System, edited by award-winning researcher, professor and author Dr. George Paxinos. The book's completely revised and updated content extends its reputation as the gold-standard reference for rat neuroanatomy. These and other books in its neuroscience portfolio are on display at Elsevier booth #115 at the Society for Neuroscience (SfN) annual meeting in Washington, DC, November 16-19.
RUK: 66.12 (+0.07), ENL: 46.79 (+0.02)

Elsevier Publishes Four New Books in Environmental Sciences Portfolio
Marketwired - Wed Nov 12, 3:00AM CST
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of four new environmental science books offering the latest information on the study of soil and water, including the fourth edition of Soil Microbiology, Ecology and Biochemistry, written by Eldor Paul, Senior Research Scientist at the Natural Resources Ecology Laboratory at Colorado State University, Fort Collins, and Professor Emeritus at Michigan State University.
RUK: 66.12 (+0.07), ENL: 46.79 (+0.02)

Sentrian, the World's First Remote Patient Intelligence Company, Launches to Eliminate Preventable Hospitalization
PR Newswire - Mon Nov 10, 7:03AM CST
Sentrian(TM) (formally Jointly Health), the Remote Patient Intelligence(TM) company aspiring to eliminate all preventable hospitalization, formally launched today at Singularity University's Exponential Medicine Conference.
RUK: 66.12 (+0.07), IBM: 164.23 (+0.07), ENL: 46.79 (+0.02)

LexisNexis: Homegrown Cardiff Company, Tracesmart(R), Creates 40 New Jobs in Cardiff
Business Wire - Wed Oct 15, 8:02AM CDT
Tracesmart, a company founded and headquartered in Cardiff, Wales, will be creating 40 jobs by the end of the year, increasing employee numbers by more than 50 percent. The new roles, based in Cardiff, include highly skilled IT developers and engineers and will support Tracesmart as it becomes the U.K. center of excellence for LexisNexis(R) Risk Solutions which acquired the company in April 2014. For more than 12 years, LexisNexis Risk Solutions has been one of the fastest-growing divisions and a key area of strategic focus of its parent company, Reed Elsevier(R), one of the world's leading providers of digital content and professional information solutions.
RUK: 66.12 (+0.07), ENL: 46.79 (+0.02)

Will John Wiley Gain from Transition to Digital Media? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 11:20AM CDT
John Wiley & Sons (JW.A) is transitioning to digitization due to soft demand for print media and recent acquisitions have a vital role to play in this. Inorganic expansion is being pursued aggressively at John Wiley and is yielding positive results as evident from the company???s first quarter fiscal 2015 results.
SCHL: 34.70 (-0.10), ENL: 46.79 (+0.02), SSP: 19.25 (+0.09), JW.A: 59.52 (+0.41)

Elsevier Publishes New Content on Graphene and Materials Science
Marketwire Canada - Thu Sep 25, 3:00AM CDT
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of new content on graphene and materials science, including Graphene: Properties, Preparation, Characterisation and Devices by Viera Skakalova and Alan Kaiser. Carbon nanotubes, graphene and nanomaterials are emerging and increasingly important materials with many applications in medicine, computing, optics, energy and materials science.
RUK: 66.12 (+0.07), ENL: 46.79 (+0.02)

Elsevier Publishes New Books on Bone and Endocrine Disease
Marketwire Canada - Thu Sep 11, 3:54AM CDT
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of four new books on bone and endocrine disease, including Bone Cancer, 2nd Edition: Primary Bone Cancers and Bone Metastases by Dominique Heymann. These biomedical science books will be on display in Elsevier's booth #101 at the upcoming American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting, September 12-15 in Houston, TX.
RUK: 66.12 (+0.07), ENL: 46.79 (+0.02)

John Wiley Beats Q1 Earnings on Strategic Acquisitions - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 9:00AM CDT
John Wiley & Sons Inc. (JW-A) reported first-quarter fiscal 2015 adjusted earnings per share of 56 cents that topped the Zacks Consensus Estimate while rising 10% year over year driven by acquisitions.
SCHL: 34.70 (-0.10), ENL: 46.79 (+0.02), JW.A: 59.52 (+0.41)

Elsevier Publishes New Chemical Engineering Content
Marketwire Canada - Wed Sep 03, 3:00AM CDT
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that new chemical engineering content is available. This content includes three new books on industrial distillation and two additional books on flow analysis and water reclamation. These books provide researchers and graduate students with latest knowledge required for those working in the oil, petrochemical, chemical, pharmaceutical and environmental industries.
RUK: 66.12 (+0.07), ENL: 46.79 (+0.02)

Elsevier to Market Innovative Patient Data Collection Platform from Tonic Health
PR Newswire Europe - Tue Sep 02, 11:24AM CDT
PHILADELPHIA, Pennsylvania, September 2, 2014 /PRNewswire/ --
RUK: 66.12 (+0.07), ENL: 46.79 (+0.02)

Elsevier Announces the Launch of Open Access Journal: 'Neurobiology of Stress'
PR Newswire Europe - Thu Aug 14, 7:19AM CDT
OXFORD, England, August 14, 2014 /PRNewswire/ --
RUK: 66.12 (+0.07), ENL: 46.79 (+0.02)

Elsevier Announces 2013 Journal Impact Factor Highlights
PR Newswire Europe - Thu Aug 14, 7:03AM CDT
AMSTERDAM, August 14, 2014 /PRNewswire/ --
RUK: 66.12 (+0.07), ENL: 46.79 (+0.02)

Elsevier Publishes First Edition of Non-Operating Room Anesthesia
PR Newswire Europe - Fri Aug 01, 6:42AM CDT
PHILADELPHIA, August 1, 2014 /PRNewswire/ --
RUK: 66.12 (+0.07), ENL: 46.79 (+0.02)

Elsevier Announces the Launch of Open Access Journal: Oral and Maxillofacial Surgery Cases
PR Newswire Europe - Mon Jul 28, 8:28AM CDT
NEW YORK, July 28, 2014 /PRNewswire/ --
RUK: 66.12 (+0.07), ENL: 46.79 (+0.02)

RELX N.V. (RENX) Stock Research Links

RENX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...